BACKGROUND: Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC. PATIENTS AND METHODS: This retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes. RESULTS: Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65\%), followed by hip/pelvis (34\%), long bones (26\%), and other sites (17\%). Median time from CRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiation and pathologic fractures affected 45\% and 10\% of patients, respectively; 32\% of patients had no reported SREs. Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival. Subgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versus 1.00 month, respectively, P = 0.009) and produced a trend toward improved overall survival versus no zoledronic acid. CONCLUSION: This study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid in this setting.
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study / Santini, D., Tampellini, M., Vincenzi, B., Ibrahim, T., Ortega, C., Virzi, V., Silvestris, N., Berardi, R., Masini, C., Calipari, N., Ottaviani, D., Catalano, V., Badalamenti, G., Giannicola, R., Fabbri, F., Venditti, O., Fratto, M.e., Mazzara, C., Latiano, T.p., Bertolini, F., et al.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 23:(2012), pp. 2072-2077. [10.1093/annonc/mdr572]
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.
BERARDI, ROSSANA;
2012-01-01
Abstract
BACKGROUND: Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC. PATIENTS AND METHODS: This retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes. RESULTS: Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65\%), followed by hip/pelvis (34\%), long bones (26\%), and other sites (17\%). Median time from CRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiation and pathologic fractures affected 45\% and 10\% of patients, respectively; 32\% of patients had no reported SREs. Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival. Subgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versus 1.00 month, respectively, P = 0.009) and produced a trend toward improved overall survival versus no zoledronic acid. CONCLUSION: This study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid in this setting.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
